We seem to have good reason for confidence over the outcome of the current trials. What seems to be lacking is a model of what success would mean from a financial perspective. Parameters embedded in such a model could be heavily qualified but still giving a feel for possible turnover and value.
If I were a potential buyer of FTT shares at this stage of product life cycle - I would be looking for this data.
FTT relative valuation suggests fair value of around 20c, page-20
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
